Trials / Completed
CompletedNCT03681184
A Study to Evaluate Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
ILLUMINATE-A: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study With an Extended Dosing Period to Evaluate the Efficacy and Safety of Lumasiran in Children and Adults With Primary Hyperoxaluria Type 1
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Alnylam Pharmaceuticals · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of lumasiran in children and adults with primary hyperoxaluria type 1 (PH1).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo by SC injection |
| DRUG | Lumasiran | Lumasiran by SC injection |
Timeline
- Start date
- 2018-11-27
- Primary completion
- 2019-11-05
- Completion
- 2024-01-12
- First posted
- 2018-09-21
- Last updated
- 2024-08-12
- Results posted
- 2021-01-19
Locations
17 sites across 8 countries: United States, France, Germany, Israel, Netherlands, Switzerland, United Arab Emirates, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03681184. Inclusion in this directory is not an endorsement.